120 related articles for article (PubMed ID: 6090353)
1. Analysis of S-35 labeled WR-2721 and its metabolites in biological fluids.
Anderson KW; Krohn KA; Grunbaum Z; Phillips RB; Mahler PA; Menard TW; Spence AM; Rasey JS
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1511-5. PubMed ID: 6090353
[TBL] [Abstract][Full Text] [Related]
2. High-performance liquid chromatographic assay using electrochemical detection for the combined measurement of amifostine, WR 1065 and the disulfides in plasma.
Korst AE; Vermorken JB; van der Vijgh WJ
J Chromatogr B Biomed Sci Appl; 1997 May; 693(1):167-74. PubMed ID: 9200531
[TBL] [Abstract][Full Text] [Related]
3. Measurement of WR-2721, WR-1065, and WR-33278 in plasma.
Fahey RC; Newton GL
Int J Radiat Oncol Biol Phys; 1985 Jun; 11(6):1193-7. PubMed ID: 2987166
[TBL] [Abstract][Full Text] [Related]
4. A method for the combined measurement of ethiofos and WR-1065 in plasma: application to pharmacokinetic experiments with ethiofos and its metabolites.
Swynnerton NF; Huelle BK; Mangold DJ; Ludden TM
Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1495-9. PubMed ID: 3019967
[TBL] [Abstract][Full Text] [Related]
5. An improved HPLC assay for S-2-(3-aminopropylamino)ethyl phosphorothioate (WR-2721) in plasma.
Swynnerton NF; McGovern EP; Niño JA; Mangold DJ
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1521-4. PubMed ID: 6090354
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a method for measuring the radioprotective metabolite WR-1065 in plasma using chemical derivatization combined with UHPLC-MS/MS.
Simon ES; Reyna D; Lister RJ; Harteg C; Lipka E
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Mar; 1080():82-89. PubMed ID: 29482122
[TBL] [Abstract][Full Text] [Related]
7. Determination of the cytoprotective agent WR-2721 (Amifostine, Ethyol) and its metabolites in human blood using monobromobimane fluorescent labeling and high-performance liquid chromatography.
Souid AK; Newton GL; Dubowy RL; Fahey RC; Bernstein ML
Cancer Chemother Pharmacol; 1998; 42(5):400-6. PubMed ID: 9771955
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic profile of amifostine.
Shaw LM; Bonner H; Lieberman R
Semin Oncol; 1996 Aug; 23(4 Suppl 8):18-22. PubMed ID: 8783662
[TBL] [Abstract][Full Text] [Related]
9. Measurement of both protein-bound and total S-2-(3-aminopropylamino)ethanethiol (WR-1065) in blood by high-performance liquid chromatography.
Bonner HS; Shaw LM
J Chromatogr B Biomed Sci Appl; 2000 Mar; 739(2):357-62. PubMed ID: 10755379
[TBL] [Abstract][Full Text] [Related]
10. Determination of the anticancer drug metabolite WR1065 using pre-column derivatization and diode laser induced fluorescence detection.
Mank AJ; Molenaar EJ; Gooijer C; Lingeman H; Velthorst NH; Brinkman UA
J Pharm Biomed Anal; 1995 Mar; 13(3):255-63. PubMed ID: 7619885
[TBL] [Abstract][Full Text] [Related]
11. HPLC assay for 2-(3-aminopropylamino)ethanethiol (WR-1065) in plasma.
McGovern EP; Swynnerton NF; Steele PD; Mangold DJ
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1517-20. PubMed ID: 6480444
[TBL] [Abstract][Full Text] [Related]
12. Measurement of WR-1065 in plasma: preliminary pharmacokinetics in the beagle.
Swynnerton NF; Huelle BK; McGovern EP; Mangold DJ; Ludden TM
Res Commun Chem Pathol Pharmacol; 1986 Nov; 54(2):255-69. PubMed ID: 3786948
[TBL] [Abstract][Full Text] [Related]
13. Tissue levels of WR-1065, the active metabolite of amifostine (Ethyol), are equivalent following intravenous or subcutaneous administration in cynomolgus monkeys.
Bachy CM; Fazenbaker CA; Kifle G; McCarthy MP; Cassatt DR
Oncology; 2004; 67(3-4):187-93. PubMed ID: 15557777
[TBL] [Abstract][Full Text] [Related]
14. Chromatographic and mass spectral analysis of the radioprotector and chemoprotector S-3-(3-methylaminopropylamino)propanethiol (WR-151326) and its symmetrical disulfide (WR-25595501).
Vaishnav YN; Pendergrass JA; Clark EP; Swenberg CE
J Pharm Biomed Anal; 1996 Jan; 14(3):317-24. PubMed ID: 8851756
[TBL] [Abstract][Full Text] [Related]
15. Interaction of cultured mammalian cells with WR-2721 and its thiol, WR-1065: implications for mechanisms of radioprotection.
Purdie JW; Inhaber ER; Schneider H; Labelle JL
Int J Radiat Biol Relat Stud Phys Chem Med; 1983 May; 43(5):517-27. PubMed ID: 6303973
[TBL] [Abstract][Full Text] [Related]
16. Blood thiols following amifostine and mesna infusions, a pediatric oncology group study.
Souid AK; Fahey RC; Aktas MK; Sayin OA; Karjoo S; Newton GL; Sadowitz PD; Dubowy RL; Bernstein ML
Drug Metab Dispos; 2001 Nov; 29(11):1460-6. PubMed ID: 11602522
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of amifostine and its metabolites in the plasma and ascites of a cancer patient.
Korst AE; Gall HE; Vermorken JB; van der Vijgh WJ
Cancer Chemother Pharmacol; 1996; 39(1-2):162-6. PubMed ID: 8995515
[TBL] [Abstract][Full Text] [Related]
18. Determination of WR-1065 and WR-33278 by liquid chromatography with electrochemical detection.
Pendergrass JA; Srinivasan V; Kumar KS; Jackson WE; Seed TM
J AOAC Int; 2002; 85(3):551-4. PubMed ID: 12083246
[TBL] [Abstract][Full Text] [Related]
19. Radioprotection of normal tissues against gamma rays and cyclotron neutrons with WR-2721: LD50 studies and 35S-WR-2721 biodistribution.
Rasey JS; Nelson NJ; Mahler P; Anderson K; Krohn KA; Menard T
Radiat Res; 1984 Mar; 97(3):598-607. PubMed ID: 6328565
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of WR-1065 in mouse tissue following treatment with WR-2721.
Utley JF; Seaver N; Newton GL; Fahey RC
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1525-8. PubMed ID: 6090355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]